Unlocking the Strategic Value of Transactional 867 Data and DDD Data

Learn how one pharmaceutical manufacturer leveraged IntegriChain’s technology to identify and close gaps in their 867 data reporting. This large pharmaceutical manufacturer developed a blockbuster drug indicated for many types of cancers. They generated more than $7 billion dollars in revenue and recognized the growing strategic business value of timely and accurate data. After heavily investing in Master Data and System Integration (MDSI) technology, data sources and personnel, they identified gaps in syndicated DDD data and 867 data.

Missing 867 data elements impacted sales operations, while missing doctor and geolocation data caused downstream problems for sales territory assignment and account planning. These data issues were compounded by the time lag of about 45 days post sale. MDSI leadership knew they had to close the gaps in 867 data and they found a solution with IntegriChain’s patient matching, national and subnational data sets and data extracts.

Download the case study below to learn how this manufacturer was able to solve their 867 data gaps and streamline their sales pipeline.